

Development of Lead Compounds for Parkinson's Disease Treatment by Regulating Adult Neurogenesis through ERR-Targeted Small Molecules



NEUROLOGY	Lead
Product Type	Small molecules
Indication	Parkinson's disease (Disease-modifying Therapy)
Target	Estrogen-related receptor gamma (ERRγ)
MoA(Mechanism of Action)	ERRγ activation enhances adult neurogenesis
Competitiveness	<ul style="list-style-type: none"> • First-in-Class in DMT • Strong BBB permeability ensuring effective CNS drug delivery
Development Stage	Lead
Route of Administration	Oral (PO)